Home > Canadian guidelines on benzodiazepine receptor agonist use disorder among older adults.

Canadian Coalition for Seniors’ Mental Health. (2019) Canadian guidelines on benzodiazepine receptor agonist use disorder among older adults. Toronto: Canadian Coalition for Seniors’ Mental Health. 26 p.

[img]
Preview
PDF (Canadian guidelines on benzodiazepine receptor agonist use disorder among older adults)
556kB
[img]
Preview
PDF (Introduction to the CCSMH guidelines on substance use disorders among older adults)
411kB

The development of this Clinical Guideline document was led by national working groups comprised of clinical and academic experts from the fields of seniors' mental health, geriatrics, and substance use and addictions. Each working group included a person whose life has been directly impacted by a substance use disorder. The Guidelines all reflect the fact that older adults are much more vulnerable to the potential adverse effects of these substances and that most individuals are also taking a variety of prescribed medications and over-the-counter products which can result in dangerous interactions.

Benzodiazepine Receptor Agonists: Drugs referred to as BZRAs act as allosteric modulators of gammaaminobutyric acid (GABA) activity by binding to inotropic benzodiazepine receptors at the GABA A receptor complex. BZRAs increase GABA binding and chloride ion channel opening, facilitating inhibitory activity. Some of these drugs have a benzodiazepine chemical structure (i.e., alprazolam, bromazepam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam, lorazepam, midazolam, nitrazepam, oxazepam, temazepam, triazolam) while others, referred to as non-benzodiazepine receptor agonists, novel benzodiazepine receptor agonists, or z-drugs (i.e., zolpidem, zopiclone), do not. We use the term BZRAs for both. Our recommendations deal with all BRZAs as they have similar benefits, side effects, and risks. These drugs have regulatory approval for the management of anxiety and panic disorders, short-term treatment of insomnia, seizures, alcohol withdrawal, sedation, and spasticity. They are also often used in an off-label manner (i.e., any use of a drug beyond what Health Canada has reviewed and authorized to be marketed in Canada and as indicated on the product label), for example to treat anxious depression or the behavioural and psychological symptoms of dementia (BPSD), which are also described as responsive behaviours.


Item Type:Evidence resource
Publication Type:Guideline
Drug Type:CNS depressants
Intervention Type:AOD disorder, AOD disorder treatment method, AOD disorder harm reduction, Psychosocial treatment method
Date:December 2019
Pages:26 p.
Publisher:Canadian Coalition for Seniors’ Mental Health
Corporate Creators:Canadian Coalition for Seniors’ Mental Health
Place of Publication:Toronto
EndNote:View
Related URLs:
Subjects:B Substances > Sedatives or tranquillisers (CNS depressants)
B Substances > Sedatives or tranquillisers (CNS depressants) > Benzodiazepine
B Substances > New (novel) psychoactive substances > Gabapentinoids GABA (Pregabalin / Gabapentin)
E Concepts in biomedical areas > Substance by legal status > Prescription drug (medicine / medication)
HJ Treatment method > Substance disorder treatment method
J Health care, prevention and rehabilitation > Patient care management
N Communication, information and education > Recommendations or guidelines > Practice / clinical guidelines
T Demographic characteristics > Elderly / Older person
VA Geographic area > Canada

Repository Staff Only: item control page